PMID- 38375342
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240221
IS  - 2666-1683 (Electronic)
IS  - 2666-1691 (Print)
IS  - 2666-1683 (Linking)
VI  - 60
DP  - 2024 Feb
TI  - Oncologic Outcomes of Testosterone Therapy for Men on Active Surveillance for 
      Prostate Cancer: A Population-based Analysis.
PG  - 36-43
LID - 10.1016/j.euros.2024.01.005 [doi]
AB  - BACKGROUND AND OBJECTIVE: There is insufficient evidence on the oncologic risks 
      of testosterone therapy for men with prostate cancer managed with active 
      surveillance. We carried out a retrospective study to assess the effect of 
      testosterone therapy on oncologic outcomes for men on active surveillance for 
      prostate cancer. METHODS: Surveillance, Epidemiology and End Results 
      (SEER)-Medicare linked data were used to identify men diagnosed with prostate 
      cancer from 2008 to 2017 who were managed with active surveillance and received 
      testosterone (n = 167) or no testosterone (n = 6658) therapy. Outcomes included 
      conversion from active surveillance to active treatment (radical prostatectomy, 
      cryotherapy, radiation, or androgen deprivation therapy), prostate 
      cancer-specific mortality, and overall mortality. Statistically significant 
      factors on univariable analysis were included in a Cox proportional-hazards 
      regression model for multivariable analysis. KEY FINDINGS AND LIMITATIONS: The 
      median age was 71 yr (interquartile range [IQR] 68-74) in the testosterone group 
      and 72 yr (IQR 69-75) in the no-testosterone group, with corresponding median 
      follow-up after prostate cancer diagnosis of 5.2 yr (IQR 3.4-7.8) and 4.7 yr (IQR 
      3.2-6.9). There were no prostate cancer-specific deaths in the testosterone group 
      and 39 (0.6%) in the no-testosterone group. Testosterone therapy was not 
      associated with conversion to active treatment (hazard ratio [HR] 0.66, 95% 
      confidence interval [CI] 0.46-0.97; p = 0.033) or overall mortality (HR 1.02, 95% 
      CI 0.68-1.53; p > 0.9). CONCLUSIONS AND CLINICAL IMPLICATIONS: In the first 
      population-based, nationally representative study of testosterone therapy for men 
      on active surveillance for prostate cancer, testosterone therapy did not increase 
      the risk of conversion to active therapy or worsen mortality. Prospective studies 
      are needed to confirm these findings. PATIENT SUMMARY: For men on active 
      surveillance for prostate cancer, we assessed the effect of testosterone therapy. 
      We found that testosterone therapy did not increase the risk of proceeding to 
      active therapy or of death from prostate cancer.
CI  - (c) 2024 The Authors.
FAU - Kaplan-Marans, Elie
AU  - Kaplan-Marans E
AD  - Division of Urology, Maimonides Medical Center, New York, NY, USA.
FAU - Zhang, Tenny R
AU  - Zhang TR
AD  - Department of Urology, NewYork-Presbyterian Hospital, New York, NY, USA.
FAU - Hu, Jim C
AU  - Hu JC
AD  - Department of Urology, NewYork-Presbyterian Hospital, New York, NY, USA.
AD  - Department of Urology, Weill Cornell Medical College, New York, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20240131
PL  - Netherlands
TA  - Eur Urol Open Sci
JT  - European urology open science
JID - 101771568
PMC - PMC10874869
OTO - NOTNLM
OT  - Active surveillance
OT  - Outcomes
OT  - Prostate cancer
OT  - Testosterone
EDAT- 2024/02/20 11:50
MHDA- 2024/02/20 11:51
PMCR- 2024/01/31
CRDT- 2024/02/20 03:43
PHST- 2024/01/12 00:00 [accepted]
PHST- 2024/02/20 11:51 [medline]
PHST- 2024/02/20 11:50 [pubmed]
PHST- 2024/02/20 03:43 [entrez]
PHST- 2024/01/31 00:00 [pmc-release]
AID - S2666-1683(24)00214-3 [pii]
AID - 10.1016/j.euros.2024.01.005 [doi]
PST - epublish
SO  - Eur Urol Open Sci. 2024 Jan 31;60:36-43. doi: 10.1016/j.euros.2024.01.005. 
      eCollection 2024 Feb.